Today's edition · Wednesday, November 4, 2026
Every story verifiedNo politics. Ever.No pop-ups
TodayLocalWorldHeroesAnimalsScienceCommunityHealth & TechMapQuizKindnessAnnouncementsKidsTopicsExplainersOn this dayCalendarGood NeighborHometown Heroes

TodayHealth & TechKentucky

Health & TechLexington, Kentucky

Kentucky's first engineered T-cell treatment for a rare sarcoma is given in Lexington

UK Markey Cancer Center administered Kentucky's first TECELRA treatment, an FDA-approved therapy that uses a patient's own genetically engineered T cells for synovial sarcoma. Care no longer requires a trip to one of a few distant centers.

Verified · Source: University of Kentucky College of MedicineNov 3, 2026 · 1 min read
How to help
Gloved hands using a pipette in a laboratory
Illustrative photo of laboratory work at the National Cancer Institute. This is not the Markey treatment. Diane A. Reid / National Cancer Institute / Wikimedia Commons · Public domain

Read the original

The reporting lives at University of Kentucky College of Medicine. Our summary is checked against it, and we link it on every story.

UK Markey Cancer Center has given Kentucky's first TECELRA treatment, the University of Kentucky College of Medicine reported. TECELRA is an FDA-approved therapy that uses a patient's own T cells after they are genetically engineered. It is for synovial sarcoma, a rare cancer, not for cancer in general.

The change the center described is where that treatment can happen. Patients who qualify no longer have to travel to one of a small number of centers outside the state. This account is the first administration in Kentucky. It does not report how this patient responded, and it does not mean the therapy is available or appropriate for every sarcoma.

More good news

Other stories in the same neighborhood of kindness.